« Return to News | Drug Sponsors

Bourne Partners, Covis Pharma acquire U.S. rights for five drugs from Sanofi

Monday, April 8, 2013 11:34 AM

Covis Pharma, a Switzerland-based specialty pharmaceutical company, has formed an agreement with Sanofi-Aventis and certain affiliates to acquire full commercial rights for Nilandron (nilutamide), Plaquenil (hydroxychloroquine), Rilutek (riluzole), Uroxatral (alfuzosin hydrochloride) and Kayexalate (sodium polystyrene sulfate) in the U.S.  

The aggregate sales for these products in the U.S. in 2012 were $114.6 million. Sanofi will retain the existing rights for these products in countries outside the U.S. Terms of the agreement have not been disclosed.

"We are very pleased to announce the addition of these products to our existing portfolio," said Jack Davis, CEO of Covis Pharma. "Covis will continue to supply consistent, top quality, branded pharmaceuticals, ensuring that patients receive the therapeutic care they need."  

Covis Pharma will promote these branded products through its U.S.-based distributor, Covis Pharmaceuticals. Covis Pharma also supplies authorized generic products to the U.S. market through a separate distributor, Rising Pharmaceuticals. Sanofi will manufacture and supply the products for Covis Pharma.

Bourne Partners acted as financial advisor to Covis Pharma on this transaction and is actively pursuing additional product and/or corporate acquisition opportunities for the company.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.